Full-Time

Senior Clinical Development Engineer

Digital

Posted on 10/5/2025

Intuitive Surgical

Intuitive Surgical

10,001+ employees

Manufactures robotic surgical systems and services

No salary listed

Sunnyvale, CA, USA

In Person

Category
Biology & Biotech (2)
,
Required Skills
Data Structures & Algorithms
Marketing
Requirements
  • Fluent in medical procedure terminology and sound knowledge of anatomy.
  • Ability to understand complex robotic systems and software algorithms.
  • Experience working in an operating room or interventional suite environment.
  • Experience collaborating with physicians and collecting feedback on clinical use of the product.
  • Excellent mechanical and technical aptitude, and intuition for spatial relations, including the ability to understand complex mechanical products.
  • Excellent analytical capability and practical skills to develop and test a clinical hypothesis and draw succinct conclusions.
  • Excellent teamwork skills with proven ability to cultivate collaboration across multiple disciplines to ensure timely project success.
  • Proven success recognizing critical issues and driving them to closure by taking coordinated action.
  • Product development and Design Controls experience.
  • Effective communication skills (verbal, written, presentation).
  • Self-starter needing minimal supervision.
  • Self-confident and able to react quickly under pressure.
Responsibilities
  • Lead and execute early-stage feasibility clinical studies, pilot and pivotal clinical trials to support technology development for regulatory and reimbursement strategies.
  • Identify and drive product enhancements and new product ideas by applying an analytical approach to understanding the clinical needs of physicians and users.
  • Collect and analyze clinical study insights to inform new product requirements, training needs, manage clinical risks adhering to quality management systems.
  • Design, develop, and execute clinical evaluations of prototypes with the ability to translate feedback to the engineering team for technology acceleration.
  • Develop intellectual property for novel clinical applications and technologies.
  • Pre-clinical research and commercial concept development: Research disease states and medical technologies associated with new business opportunities to become an expert on new products and their clinical applications.
  • Collaborate with marketing partners and clinicians to identify and understand marketing needs.
  • Work with key opinion leaders, subject matter experts, and other stakeholders to identify clinical goals and translate those needs into user-centric designs for new platforms, procedures, instruments, and accessories.
  • Collaborate closely with engineers and physicians to define and evaluate clinical performance goals, potential safety and usability risks for new products in early-phase development.
  • Develop and execute clinical derisking pathways, including pre-clinical and clinical feasibility studies, to ensure technology advancement and readiness for commercial launch.
  • Conduct design iteration assessments of products both internally and with external key opinion leaders.
  • Develop and execute a preclinical evaluation strategy in advance of human trials and for regulatory submissions.
  • Provide subject matter expertise to user manual and training documentation development.
  • Support regulatory documentation and submissions.
  • Demonstrate an analytical approach to identify potential product enhancements and new product ideas.
Desired Qualifications
  • Experience with on-site clinical trial support.
  • Experience with commercial product launch.
  • Familiar with intellectual property development and patent assessment.

Intuitive Surgical designs, manufactures, and sells robotic surgical systems and provides related services and accessories for minimally invasive surgery. The core product helps surgeons perform operations with enhanced precision by guiding robotic arms controlled from a console, allowing procedures to be done through small incisions. Instruments and consumables are used with the systems and are supported by service contracts, creating a recurring revenue stream. Compared to competitors, Intuitive has a large installed base and focuses specifically on robotic-assisted surgery, combining devices, disposable instruments, and ongoing services to support hospitals and surgical centers. Its goal is to improve patient outcomes by enabling safer, less invasive procedures while expanding the use and capabilities of robotic surgery for more procedures and providers.

Company Size

10,001+

Company Stage

IPO

Headquarters

Sunnyvale, California

Founded

1995

Simplify Jobs

Simplify's Take

What believers are saying

  • Bariatric surgery market expansion as da Vinci outperforms GLP-1 drugs for sustained weight loss.
  • Ion bronchoscopy system procedures grew 39% YoY with 1,041 installed units capturing lung cancer detection.
  • Less than 5% of eligible surgeries globally performed robotically indicates substantial international adoption runway.

What critics are saying

  • FDA Class II recalls of instruments with fraying cables disrupt 86% of Q1 recurring revenue.
  • FDA safety communication on curved tip staplers halts hospital use, eroding surgeon confidence in reliability.
  • EU MDR recertification deadline December 2028 halts 25% European sales during redesign and testing.

What makes Intuitive Surgical unique

  • 70-80% market share in soft-tissue robotics with 11,395 installed da Vinci systems globally.
  • 85% recurring revenue from instruments, accessories, and service contracts provides predictable cash flow.
  • da Vinci 5 platform expands into cardiac surgery and complex procedures previously requiring open surgery.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Apr 7th, 2026
Intuitive Surgical emerges as dark horse in anti-obesity market as surgery outperforms GLP-1 drugs

Intuitive Surgical could emerge as a dark horse in the anti-obesity market as bariatric surgery proves more effective than GLP-1 drugs for long-term weight loss. A recent study of over 50,000 patients found surgery patients lost an average of 58 pounds after two years, compared to just 12 pounds for those using GLP-1 medications. The study also showed surgery delivers more sustainable results. Gastric bypass patients maintain around 52% of their excess weight loss after 10 years, whilst GLP-1 users often regain all lost weight after stopping treatment. Intuitive's da Vinci surgical system offers minimally invasive bariatric surgery options. The company generated $10.1 billion in revenue last year, up from $8.4 billion, with profit margins around 28%. Despite shares falling over 20% this year, the company's position in surgical innovation makes it a compelling long-term investment.

Yahoo Finance
Mar 29th, 2026
Intuitive Surgical shares drop 19% YTD, but analysts see 15% upside potential

Intuitive Surgical has experienced recent share price weakness, declining 3% in one day with negative returns over the past week, month and three months. The stock currently trades at $452.66, down 10.1% over one month and 19.45% year-to-date, though three-year total shareholder returns remain strong at 77.19%. The medical technology company reports annual revenue of $10.1 billion and net income of $2.9 billion, maintaining a dominant position in minimally invasive surgical technology. According to one valuation analysis, Intuitive Surgical's fair value sits at $532.46, suggesting the stock is undervalued by approximately 15% at current levels. The analysis projects 12% annual revenue growth over the next five years, supported by recurring revenues from spare parts and software licences, with profit margins expected to reach 30% from the current 28.6%.

Yahoo Finance
Mar 28th, 2026
Intuitive Surgical shares up 23% after Jim Cramer's buy recommendation

Intuitive Surgical shares rose 23% following Jim Cramer's recommendation on CNBC's Squawk on the Street in June 2025, where he urged investors to "just go buy ISRG". The medical robotics company experienced a 27% surge in October after reporting third-quarter earnings that beat analyst estimates. Revenue reached $2.51 billion against expectations of $2.40 billion, whilst adjusted earnings per share hit $2.40 versus the predicted $1.98. However, the stock declined 2.7% in January 2026 after Intuitive Surgical released preliminary fourth-quarter results, citing concerns that Medicaid funding cuts and competing products could slow growth of its robotic surgical systems. Despite the recent setback, shares remain up significantly since Cramer's initial endorsement, though they're down 7.8% over the past year.

Yahoo Finance
Mar 28th, 2026
Intuitive Surgical faces tariff headwinds and rising competition despite 19% revenue growth to $2.87B

Intuitive Surgical faces headwinds from tariffs and increased competition in the robotic-assisted surgery market, yet its fundamentals remain strong. The medical device company reported fourth-quarter revenue growth of 19% to $2.87 billion, whilst adjusted earnings per share rose 14.5% to $2.53. Procedures using its da Vinci surgical system increased 17%, with the installed base growing 12% to 11,106 units. However, the stock trades at 47.6 times forward earnings, compared to the healthcare sector average of 17.1. New competition is emerging, with Medtronic's Hugo system recently cleared and Johnson & Johnson expected to launch its own device soon. Despite these challenges, Intuitive Surgical maintains advantages through switching costs and extensive real-world data, whilst the underpenetrated robotic-assisted surgery market offers long-term growth potential.

Yahoo Finance
Mar 24th, 2026
ISRG maintains 37% operating margins in Q4 despite 95 bps tariff drag

Intuitive Surgical maintained a 37% operating margin in Q4 despite tariffs creating a 95 basis point drag, alongside higher facility costs and unfavourable product mix from newer platforms like da Vinci 5 and Ion. The company offset these pressures through product cost reductions, component savings and manufacturing efficiencies. Procedure growth of 18% in Q4 and recurring revenue now comprising 81% of total revenues provided operating leverage. Management's 2026 gross margin guidance of 67-68% suggests continued stability, even as tariff headwinds are expected to increase to roughly 1.2% of revenues. Meanwhile, Boston Scientific expanded adjusted operating margins by 100 basis points to 28% in 2025, though tariffs will offset favourable product mix in 2026. The company expects 50-75 basis points operating margin expansion in 2026 through scale efficiencies and supply-chain optimisation.

INACTIVE